Part I: Checkpoint inhibitors in cancer therapy. - Wikidata - awgldk - TriplyDB

Part I: Checkpoint inhibitors in cancer therapy.

Part I: Checkpoint inhibitors in cancer therapy.

http://www.wikidata.org/entity/Q45958620

about

Welcome to the 9th Volume of Immunotherapy.

P2860

Q38779882-E4F84677-2577-457B-811D-9BC87196F232

P2860

Part I: Checkpoint inhibitors in cancer therapy.

http://www.wikidata.org/entity/Q45958620

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Part I: Checkpoint inhibitors in cancer therapy.

@en

Part I: Checkpoint inhibitors in cancer therapy.

@nl

type

label

Part I: Checkpoint inhibitors in cancer therapy.

@en

Part I: Checkpoint inhibitors in cancer therapy.

@nl

prefLabel

Part I: Checkpoint inhibitors in cancer therapy.

@en

Part I: Checkpoint inhibitors in cancer therapy.

@nl

P1433

Q45958620-630593C8-A403-4CF2-AF98-714D1BE4F7BD

P1476

Q45958620-3F9D8798-4987-411A-B9BA-CC4A9DB35584

P2093

Q45958620-B76186CD-002D-4C6F-B8E3-C1A70F7B61D2

P2860

Q45958620-1802951E-0709-4A96-A155-DB54A1DBE93E

Q45958620-1D7092AF-619A-45DE-8741-A12F000A8BB4

Q45958620-29C2B703-A27C-4E01-96C3-776176A53C35

Q45958620-39427D35-8782-4268-A627-E5EEAEEA40B0

Q45958620-5B0D7B5A-8A05-4D05-A9AA-1D2EBD9B0F52

Q45958620-864327C9-7366-44FD-8D1E-BAD1EB377E52

Q45958620-8CE236FE-66B5-473E-A640-572839CC811A

P304

Q45958620-0121AC4F-6999-41AC-AE23-AE2B013ED69A

P31

Q45958620-B71C1C75-EB83-4276-8785-CC68C6EF7DE1

P356

Q45958620-2F93165D-1D82-42A4-A7E9-30D979B95485

P433

Q45958620-FA5DBDA5-DA26-4125-BE38-3AA8BD1A39A9

P478

Q45958620-8C53D613-2CC0-4508-9E0C-EB5C91CBCB25

P50

Q45958620-33A30FDA-CC66-4641-81FF-CC857E60E948

P577

Q45958620-121E5B2A-0F11-4551-891B-BC7AC6A1ADD3

P698

Q45958620-C13F9316-C270-40AF-BD78-A63F3334D985

P356

P1433

P1476

Part I: Checkpoint inhibitors in cancer therapy

@en

P2093

Adil I Daud

http://www.w3.org/2001/XMLSchema#string

P2860

Are there, or shall we discover, biomarkers to guide PD-1 inhibition?

Checkpoint inhibition for colorectal cancer: progress and possibilities.

Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.

Checkpoint inhibition in meningiomas.

PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.

Targeting PD-L1 for non-small-cell lung cancer.

Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.

P304

675-676

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2016-0051

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27197535

http://www.w3.org/2001/XMLSchema#string